VP2-TALE fusions increase AAV2 capsid filling with payload bearing cognate TALE target sequences as determined by qPCR/ELISA
Molecular Therapy Advances · 2026-12 · 34 (4) · 201877
DOI: 10.1016/j.omta.2026.201877 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy Advances, 2026-12. Verfasst von Qiantong Chen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemical Engineering, University College London, Bernard Katz Building, London WC1E 7JE, UK. Die Arbeit nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Engineering and Physical Sciences Research Council.
Abstract (Originalsprache)
We sought to improve the empty/full ratio of recombinant adeno-associated virus serotype 2 (AAV2) production by engineering the capsid to increase the favorability of its interactions with payload genomes. We fused a transcription activator-like effector (TALE), sequence-specific DNA-binding domain to the VP2 protein (VP2-TALE), either directly or via flexible linkers, within a transgene encoded by an overexpression plasmid. We also engineered seven different versions of the green fluorescent protein (GFP) payload plasmid, with up to three copies of a 14 base-pair TALE-cognate target sequence. Co-transfection with a helper plasmid, a RepCap plasmid engineered to prevent native VP2 expression, and a VP2-TALE expression plasmid resulted in lower capsid titers and higher viral genome titers when TALE target sequences were present in the payload plasmid than in control transfections in which the payload lacked TALE target sequences. Western blotting with an anti-VP antibody showed VP-positive proteins of the size predicted for VP2-TALE fusion. Electron microscopy indicated the presence of correctly formed viral capsids. ELISA and qPCR analysis indicated that these transfections could result in increases in capsid filling approaching 200%.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biochemical Engineering, University College London, Bernard Katz Building, London WC1E 7JE, UK.
- Cytiva Life Sciences, Amersham Place, Little Chalfont, Amersham HP7 9NA, UK.
- Institute of Neuropathology, University Hospital Zurich, Schmelzbergstrasse 12, 8091 Zurich, Switzerland.
Förderung
- Engineering and Physical Sciences Research Council
Zitieren
APA
Chen, Q., Bal, M., Howe, G., Whitfield, R., & Nesbeth, D. N. (2026). VP2-TALE fusions increase AAV2 capsid filling with payload bearing cognate TALE target sequences as determined by qPCR/ELISA. Molecular Therapy Advances, 34(4), 201877. https://doi.org/10.1016/j.omta.2026.201877
Vancouver
Chen Q, Bal M, Howe G, Whitfield R, Nesbeth DN. VP2-TALE fusions increase AAV2 capsid filling with payload bearing cognate TALE target sequences as determined by qPCR/ELISA. Molecular Therapy Advances. 2026;34(4):201877. doi:10.1016/j.omta.2026.201877
BibTeX
@article{Chen2026,
author = {Chen, Qiantong and Bal, Mehtap and Howe, Geoffrey and Whitfield, Robert and Nesbeth, Darren N},
title = {VP2-TALE fusions increase AAV2 capsid filling with payload bearing cognate TALE target sequences as determined by qPCR/ELISA},
journal = {Molecular Therapy Advances},
year = {2026},
volume = {34},
number = {4},
pages = {201877},
doi = {10.1016/j.omta.2026.201877}
}
EUVIMED